

Watauga Opioid Settlement Grant FY 25-26

Project Worksheet

The purpose of this worksheet is to gather a **high level overview** of potential Watauga Opioid Settlement projects that will allow AppHealthCare to collect project details for the Review Committee as well as the County Commissioners. It is not an application form and does not require the detailed level of information that would be expected in an application. This worksheet was adapted from a similar tool developed by Golden LEAF Foundation. This worksheet includes three parts: Project Overview, Project Budget, and Project Outcomes. Please complete all three parts or indicate that the information is not available. If necessary, in your responses you can include links to outside resources, or you may attach additional information.

AppHealthCare understands that potential applicants may not have answers to all of the questions at this time. Responses to these questions should be brief and focused. Projects will be prioritized based on American Society of Addiction Medicine (ASAM) guidelines.

If you have any questions about this form, please contact grants@apphealth.com. Questions are due to grants@apphealth.com March 28th by 5pm. This worksheet is due to grants@apphealth.com April 4th by 5pm.

| | |
|------------------------------|--|
| Organization | |
| Project Contact Name | |
| Project Contact Role | |
| Project Contact Email | |

You will have the opportunity to list additional key staff later in this document.

Project Overview

1. **What is the issue or need that your project addresses? If available, include data or documentation that helps define the issue or need. *(limited to 1500 characters)***

2. **Which of the Exhibit A strategies (see attachment) does your project align with? How does it align? *(limited to 1500 characters)*:**

3. **Describe the key elements and major activities of your project, including a timeline of implementation. If applicable, share the evidence behind any programming you plan to offer. (limited to 1500 characters)**

4. **Who will you serve with this effort? If applicable, share how eligibility will be determined and/or referrals will work. Share how individuals with lived or living experience with opioid use will inform and/or lead your project. (limited to 1500 characters)**

5. **Complete the project budget form included in this document.**

6. **Complete the appropriate checklist at the end of this document based on the Exhibit A Strategy you have selected. **You only need to complete the checklist that aligns with your strategy**.** Projects are not expected to address all priority outcomes. However, ****you must select at least one measure in EACH color, and it is strongly suggested to select additional measures****. If needed, sites may develop their own outcomes with support of AppHealthCare/Opioid Settlement Technical Assistance Team (OSTAT) by emailing grants@apphealth.com to schedule a call prior to the deadline.

7. **After completing the checklist, please share how you plan to collect this data and what success would look like. How will your project generate community-wide impact? (limited to 1500 characters)**

8. List the key staff involved in implementing the project.

| Name | Role | Relevant Duties |
|-------------|-------------|------------------------|
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |

Describe how the above staff are essential to the project's success, as well as how your organization is particularly suited to implement this project. Share any prior successes that can be built upon and/or existing work that can be leveraged. (limited to 1500 characters)

9. Who else is working on this issue or similar issues in your community? List potential partners and/or organizations that you plan to collaborate with.

| Partner/Organization | County | Relevant Programs/Services |
|----------------------|--------|----------------------------|
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |

Describe how collaboration and/or partnership will be demonstrated with your project, including with the partners listed above. Please address any potential overlap or duplication that could occur with your project and similar efforts in the county (including with partners/organizations not listed). *(limited to 1500 characters)*

10. Describe the potential for longevity with your project. What are the goals of your project that extend beyond this fiscal year that could make it a good multi-year investment? Alternatively, how do you plan to address sustainability of the project outside of opioid settlement funds? *(limited to 1500 characters)*

Project Budget

Complete the project budget form below by inserting a dollar amount in the appropriate cells. **The target range for projects is \$75,000- \$150,000.** The budget does not have to be final, but should give a general idea of the amount to be requested of Watauga County and the amount needed from other sources. The form includes a few high-level budget categories for your use. More detailed information is not required. *You may add other categories in the remaining cells on the Line Item column if needed.*

| Line Item | Opioid Settlement Request (in dollars) | Other Funding Sources (Committed) (in dollars) | Other Funding Sources (Requested) (in dollars) |
|---------------------------------|---|--|---|
| Personnel | \$ | \$ | \$ |
| Fringe Benefits | \$ | \$ | \$ |
| Equipment | \$ | \$ | \$ |
| Rent | \$ | \$ | \$ |
| Supplies | \$ | \$ | \$ |
| Professional Development | \$ | \$ | \$ |
| Contracted Services | \$ | \$ | \$ |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| TOTAL: | \$ | \$ | \$ |

Project Outcomes

What specific outcomes will you address? **Find the appropriate list below based on the Exhibit A Strategy you have selected. *You only need to complete the checklist that aligns with your strategy*.** Projects are not expected to address all priority outcomes. However, ***you must select at least one measure in EACH color, and it is strongly suggested to select additional measures*.** If needed, sites may develop their own outcomes with support of AppHealthCare/Opioid Settlement Technical Assistance Team (OSTAT) by emailing grants@apphealth.com to schedule a call prior to the deadline.

Exhibit A Strategy 1 ‘Collaborative strategic planning’

- # of staff hired to lead Collaborative Strategic Planning efforts related to the Opioid Settlements
- # of meetings facilitated to support Collaborative Strategic Planning efforts related to the Opioid Settlements
- # of collaborative strategic plans produced, in which all of the activities below were completed
- # of recommendations that were approved by local officials AND total # of recommendations offered to local officials
- # of stakeholder categories (as outlined in Exhibit C Item A Detail) that were met during the collaborative strategic planning process
- # of stakeholders involved in the collaborative strategic planning process who reported that they feel heard in the process AND total # of stakeholders involved in the collaborative strategic planning process
- # of recommendations implemented during the reporting period AND total # of recommendations that were approved by local officials
- Other (please list): _____

Exhibit A Strategy 2 ‘Evidence-based addiction treatment’

- # of naloxone kits distributed
- # of OTPs that dispense methadone, buprenorphine, and naltrexone
- # of OTPs that dispense only methadone
- # of OTP-based medical providers who prescribe methadone for OUD patients
- # of referrals to opioid treatment programs
- # of unique patients with OUD served at OTP
- # of office-based clinics offering MOUD within county
- # of individual OBOT providers who prescribe buprenorphine for patients
- # of buprenorphine prescriptions provided at OBOT
- # of naltrexone doses provided at OBOT
- # of referrals to OBOT
- # of unique patients with OUD served at OBOT
- # of FQHCs offering MOUD within county
- # of individual FQHC providers who prescribe buprenorphine for patients
- # of buprenorphine prescriptions provided at FQHC
- # of naltrexone doses provided at FQHC
- # of referrals to FQHC MAT services
- # of unique patients with OUD served at FQHC
- # of hospitals offering in-patient MOUD within county
- # of hospitalists who prescribe buprenorphine for patients
- # of buprenorphine prescriptions provided through in-patient services in hospitals
- # of naltrexone doses provided through in-patient services in hospitals
- # of referrals to in-patient MAT services
- # of unique hospital in-patients with OUD served with MAT
- # of emergency departments offering MOUD within county
- # of emergency department providers who prescribe buprenorphine for patients
- # of short-term buprenorphine prescriptions (14 days or less) provided in the ED
- # of longer-term buprenorphine prescriptions (15 days or more) provided in the ED
- # of naltrexone doses provided in the emergency department
- # of referrals from emergency department to community providers
- # of unique emergency department patients with OUD served with MAT
- # of Local Health Departments (LHD) offering MOUD within county
- # of individual LHD-based providers who prescribe buprenorphine for patients
- # of buprenorphine prescriptions provided at LHD
- # of naltrexone doses provided at LHD
- # of referrals to LHD MAT services
- # of unique patients with OUD served at LHD with MAT
- # of EMS programs offering MOUD within county
- # of individual EMS providers who prescribe buprenorphine for patients
- # of buprenorphine prescriptions provided through EMS-based MAT programs
- # of naltrexone doses through EMS-based MAT programs
- # of referrals to EMS-based MAT programs
- # of unique patients who received pre-hospital buprenorphine treatment from EMS during a non-fatal overdose encounter
- # of unique patients with OUD served through EMS-based MAT programs
- # of unique patients with OUD who declined services through EMS-based MAT programs

- # of Syringe Service Programs (SSPs) offering MOUD within county
- # of providers who prescribe buprenorphine for patients at/through an SSP
- # of buprenorphine prescriptions provided through SSPs
- # of naltrexone doses provided through SSPs
- # of referrals to SSP-based MAT services
- # of unique patients with OUD served through SSPs with MAT
- # of patients who are justice-involved that are referred to any MAT program

***REQUIRED* # of unique patients who have OUD, served**

• Of the # of unique patients who have OUD, served in the count above, how many people identified as:

- American Indian/Alaska Native Non-Hispanic
- Asian Non-Hispanic
- Black Non-Hispanic
- Native Hawaiian or Other Pacific Islander Non-Hispanic
- White Non-Hispanic
- Hispanic
- Some Other Race or Multiple Races
- Unknown

- # of referrals to opioid treatment programs that resulted in 1st appointment attended AND total # of referrals to opioid treatment programs
- # of referrals to OBOT services that resulted in 1st appointment attended at office-based clinic AND total # of referrals to OBOT services at office-based clinic
- # of referrals to OBOT services that resulted in 1st appointment attended at FQHC AND total # of referrals to OBOT services at FQHC
- # of referrals to OBOT services that resulted in 1st appointment attended at LHD AND total # of referrals to OBOT services at LHD
- # of referrals to EMS-based MAT programs that resulted in 1st appointment for treatment attended AND total # of referrals to EMS-based MAT programs
- # of referrals to SSP-based MAT services that resulted in 1st appointment for treatment attended AND total # of referrals to SSP-based MAT services
- # of patients who are justice-involved that are referred to any MAT program that resulted in 1st appointment for treatment attended AND total # of patients who are justice-involved that are referred to any MAT program
- # of unique patients who have OUD, served, who report they are satisfied with services AND total # of unique patients who have OUD, served
- # of unique patients with OUD served who were connected and adhere to treatment AND total # of unique patients who have OUD, served
- # of patients who have OUD, served who report getting the social and emotional support they need AND total # of unique patients who have OUD, served
- # of community overdose reversals using naloxone
- Other (please list): _____

Exhibit A Strategy 3 ‘Recovery support services’

***REQUIRED* # of unique participants, who use opioids and/or have OUD, served**

• Of the # of unique participants, who use opioids and/or have OUD, served in the count above, how many people identified as:

- **American Indian/Alaska Native Non-Hispanic**
- **Asian Non-Hispanic**
- **Black Non-Hispanic**
- **Native Hawaiian or Other Pacific Islander Non-Hispanic**
- **White Non-Hispanic**
- **Hispanic**
- **Some Other Race or Multiple Races**
- **Unknown**

- # of total contacts with all participants of the program
- # of participants who use opioids and/or have OUD, referred to addiction treatment
- # of participants who use opioids and/or have OUD, referred to recovery supports (e.g., employment services, housing services, etc.)
- # of participants who use opioids and/or have OUD, referred to harm reduction services (e.g., syringe and supply access, overdose prevention education, disease prevention, etc.)
- # of participants who use opioids and/or have OUD, referred to primary healthcare
- # of participants who use opioids and/or have OUD, referred to other services
- # of peer support specialists/care navigators
- # of naloxone kits distributed
- # of unique participants, who use opioids and/or have OUD, served, who report they are satisfied with services AND total # of unique participants, who use opioids and/or have OUD, served
- # of referrals to addiction treatment, recovery supports, harm reduction services, primary healthcare, and other services that result in linkage to supports/services AND total # of referrals to addiction treatment, recovery supports, harm reduction services, primary healthcare, and other services
- # of staff with lived experience with OUD AND total # of staff
- # of unique participants, who use opioids and/or have OUD, served who received naloxone kit AND total # of unique participants, who use opioids and/or have OUD, served
- # of unique participants with OUD served who were connected to treatment and adhered to treatment AND total # of participants who use opioids and/or have OUD, referred to addiction treatment
- # of unique participants with OUD served who were connected to employment services and obtained employment AND total # of participants who use opioids and/or have OUD, referred to recovery supports (e.g., employment services, housing services, etc.)
- # of unique participants with OUD served who retain permanent housing at 6 months AND total # of participants who use opioids and/or have OUD, referred to recovery supports (e.g., employment services, housing services, etc.)
- # of unique participants with OUD served who were connected to harm reduction services and remained engaged with services AND total # of participants who use opioids and/or have OUD, referred to harm reduction services
- # of unique participants with OUD served who were connected to primary healthcare services and who kept using services AND total # of participants who use opioids and/or have OUD, referred to primary healthcare
- # of unique participants with OUD served who were connected to other services and who kept using services AND total # of participants who use opioids and/or have OUD, referred to other services
- # of participants who use opioids and/or have OUD, served who report getting the social and emotional support they need AND total # of participants who use opioids and/or have OUD, served
- Other (please list): _____

Exhibit A Strategy 4 ‘Recovery housing support’

***REQUIRED* # of unique patients who have OUD, served**

● Of the # of unique patients who have OUD, served in the count above, how many people identified as:

- American Indian/Alaska Native Non-Hispanic
- Asian Non-Hispanic
- Black Non-Hispanic
- Native Hawaiian or Other Pacific Islander Non-Hispanic
- White Non-Hispanic
- Hispanic
- Some Other Race or Multiple Races
- Unknown

- # of people with OUD who received assistance with rent
- # of people with OUD who received assistance with application fees
- # of people with OUD who received assistance with deposits
- # of people with OUD who received assistance with utilities
- # of programs where access is not contingent on sobriety, min. income requirements, lack of a criminal record, completion of treatment, participation in services, or other unnecessary conditions
- # of programs with services which are informed by a harm-reduction philosophy that recognizes that drug and alcohol use and addiction are a part of some tenants’ lives
- # of programs where substance use in and of itself, without other lease violations, is not considered a reason for eviction
- # of programs in contact with the HUD-funded Continuum of Care (CoC) or Balance of State Continuum of Care (BoS CoC) for your area
- # of naloxone kits distributed
- # of people with OUD who received assistance with rent AND total # of people with OUD who requested assistance with rent
- # of people with OUD who received assistance with application fees AND total # of people with OUD who requested assistance with application fees
- # of people with OUD who received assistance with deposits AND total # of people with OUD who requested assistance with deposits
- # of people with OUD who received assistance with utilities AND total # of people with OUD who requested assistance with utilities
- # of participants with OUD who have achieved their individual plans/treatment goals AND total # of participants with OUD who have individual plans/treatment goals
- # of unique participants who have OUD, served, who needed crisis services/hospitalization AND total # of unique participants who have OUD, served
- Average # of days from initial referral to primary engagement
- # of unique patients who have OUD, served, who report they are satisfied with services AND total # of unique participants who have OUD, served
- # of Housing First or related programs available to connect people who use drugs to housing services
- # of unique participants who have OUD, served who retain permanent housing at 6 months AND total # of unique participants who have OUD, served
- # of unique participants who have OUD, served who retain permanent housing at one year AND total # of unique participants who have OUD, served
- # of participants who have OUD, served who report getting the social and emotional support they need AND total # of unique participants who have OUD, served
- # of community overdose reversals using naloxone
- Other (please list): _____

Exhibit A Strategy 5 ‘Employment-related services’

***REQUIRED* # of unique patients who have OUD, served**

• Of the # of unique patients who have OUD, served in the count above, how many people identified as:

- American Indian/Alaska Native Non-Hispanic**
- Asian Non-Hispanic**
- Black Non-Hispanic**
- Native Hawaiian or Other Pacific Islander Non-Hispanic**
- White Non-Hispanic**
- Hispanic**
- Some Other Race or Multiple Races**
- Unknown**

- # of job training sessions offered
- # of job skill building trainings offered
- # of people assisted with job placement
- # of interview coaching session offered
- # of resume review sessions offered
- # of participants who received professional attire
- # of participants in community college courses
- # of requests for transportation assistance fulfilled
- # of transportation vouchers distributed
- # of naloxone kits distributed
- # of unique participants who have OUD, served, who report they are satisfied with services AND total # of unique participants who have OUD, served
- # of unique participants who have OUD, who attended job training and showed improvement from pre-test to post-test AND total # of unique participants who have OUD, who attended job training
- # of unique participants who have OUD, who attended job training and then sought job placement services AND total # of unique participants who have OUD, who attended job training
- # of unique participants who have OUD, who attended interview coaching session and improved their interviewing skills AND total # of unique participants who have OUD, who attended interview coaching session
- # of unique participants who have OUD, who attended resume review session and improved their resumes AND total # of unique participants who have OUD, who attended resume review session
- # of unique participants who have OUD, served who say they have the professional attire needed AND total # of unique participants who have OUD, served
- # of participants in community college courses, who completed their course(s) AND total # of participants in community college courses
- # of requests for transportation assistance fulfilled AND total # of requests for transportation assistance
- # of transportation vouchers used AND total # of transportation vouchers distributed
- # of people assisted with job placement who are employed 6 months after placement AND total # of people assisted with job placement
- # of participants who have OUD, served who report getting the social and emotional support they need AND total # of unique participants, who have OUD, served
- Other (please list): _____

Exhibit A Strategy 6 ‘Early Intervention’

of Youth Mental Health First-Aid training programs held

***REQUIRED* # of unique participants trained**

● **Of the # of participants trained in the count above, how many people identified as:**

- **American Indian/Alaska Native Non-Hispanic**
- **Asian Non-Hispanic**
- **Black Non-Hispanic**
- **Native Hawaiian or Other Pacific Islander Non-Hispanic**
- **White Non-Hispanic**
- **Hispanic**
- **Some Other Race or Multiple Races**
- **Unknown**

of trainers who provide Youth Mental Health First-aid programs

of peer-based training programs held

of unique participants trained in peer-based program

of trainers who provide peer-based programs

of other early intervention training programs held

of unique participants trained in other early intervention programs

of trainers who provide other early intervention programs

of unique participants trained, who are satisfied w/ training AND total # of unique participants trained

of unique participants trained, who feel more confident in supporting children and adolescents who may be struggling AND total # of unique participants trained

of unique participants trained, who improved skills in supporting children and adolescents who may be struggling AND total # of unique participants trained

of unique participant trained, who improved knowledge in supporting children and adolescents who may be struggling AND total #of unique participants trained

of unique participants trained, who report using skills/knowledge gained in training AND total # of unique participants trained

of unique participants trained, who report getting the social and emotional support they need AND total # of unique participants trained

% of short-term suspensions

of community overdose reversals using naloxone

Other (please list): _____

Exhibit A Strategy 7 ‘Naloxone distribution’

***REQUIRED* # of unique participants who have OUD, served**

- **Of the # of unique participants who have OUD, served in the count above, how many people identified as:**
 - **American Indian/Alaska Native Non-Hispanic**
 - **Asian Non-Hispanic**
 - **Black Non-Hispanic**
 - **Native Hawaiian or Other Pacific Islander Non-Hispanic**
 - **White Non-Hispanic**
 - **Hispanic**
 - **Some Other Race or Multiple Races**
 - **Unknown**
- # of intramuscular naloxone kits distributed
- # of intranasal naloxone kits distributed
- # of trainings on harm reduction (e.g., overdose prevention, safer use practice, disease prevention) provided
- # of people trained in harm reduction
- # of naloxone trainings
- # of people trained on naloxone
- # of unique participants, who use opioids and/or have OUD, served, who report they are satisfied with services AND total # of unique participants, who use opioids and/or have OUD, served
- # of naloxone distributed to EMS AND total # of naloxone kits distributed
- # of naloxone distributed to hospital ED AND total # of naloxone kits distributed
- # of naloxone distributed to community based organizations AND total # of naloxone kits distributed
- # of naloxone distributed to firefighters AND total # of naloxone kits distributed
- # of naloxone distributed to police AND total # of naloxone kits distributed
- # of those trained on naloxone, who report they know how to respond to an opioid overdose and administer naloxone AND total # of people trained on naloxone
- # of months in past year that program had to ration naloxone
- # of community overdose reversals using naloxone
- # of patients who were visited by EMS more than once because of overdose
- # of patients who were admitted to the ED more than once because of overdose
- # of patients who have OUD, served who report getting the social and emotional support they need AND total # of unique participants, who use opioids and/or have OUD, served
- Other (please list): _____

Exhibit A Strategy 8 'Post-overdose response team'

***REQUIRED* # of unique participants who have OUD, served**

● Of the # of unique participants who have OUD, served in the count above, how many people identified as:

- American Indian/Alaska Native Non-Hispanic
- Asian Non-Hispanic
- Black Non-Hispanic
- Native Hawaiian or Other Pacific Islander Non-Hispanic
- White Non-Hispanic
- Hispanic
- Some Other Race or Multiple Races
- Unknown

- # of established agency-level network partners
- # of referrals to PORT following an overdose reversal
- # of people who experience an overdose who agree to talk with a PORT member
- # of total contacts with all participants who use opioids and/or have OUD
- # of participants who use opioids and/or have OUD referred to addiction treatment
- # of participants who use opioids and/or have OUD referred to recovery supports (e.g., employment services, housing services, etc.)
- # of participants who use opioids and/or have OUD referred to harm reduction services (e.g., syringe and supply access, overdose prevention education, disease prevention, etc.)
- # of participants who use opioids and/or have OUD referred to primary healthcare
- # of participants who use opioids and/or have OUD referred to other services
- # of naloxone kits distributed
- # of unique participants, who use opioids and/or have OUD, served, who report they are satisfied with services AND total # of unique participants, who use opioids and/or have OUD, served
- # of EMS calls for opioid overdose AND total # of EMS calls
- # of unique participants with OUD served who were connected to treatment and adhered to treatment AND total # of participants who use opioids and/or have OUD, referred to addiction treatment
- # of unique participants with OUD served who were connected to employment services and obtained employment AND total # of participants who use opioids and/or have OUD, referred to recovery supports (e.g., employment services, housing services, etc.)
- # of unique participants with OUD served who were connected to housing services and retained housing AND total # of participants who use opioids and/or have OUD, referred to recovery supports (e.g., employment services, housing services, etc.)
- # of unique participants with OUD served who were connected to harm reduction services and remained engaged with harm reduction services AND total # of participants who use opioids and/or have OUD, referred to harm reduction services
- # of unique participants with OUD served who were connected to primary healthcare services and who kept using services AND total # of participants who use opioids and/or have OUD, referred to primary healthcare
- # of unique participants with OUD served who were referred to other services and who kept using services AND total # of participants who use opioids and/or have OUD, referred to other services
- # of participants who use opioids and/or have OUD, served who report getting the social and emotional support they need AND total # of participants who use opioids and/or have OUD, served
- # of community overdose reversals using naloxone
- Other (please list): _____

Exhibit A Strategy 9 ‘Syringe service program’

***REQUIRED* # of unique participants who have OUD, served**

● Of the # of unique participants who have OUD, served in the count above, how many people identified as:

- American Indian/Alaska Native Non-Hispanic
- Asian Non-Hispanic
- Black Non-Hispanic
- Native Hawaiian or Other Pacific Islander Non-Hispanic
- White Non-Hispanic
- Hispanic
- Some Other Race or Multiple Races
- Unknown

- # of total contacts the program had with all participants
- # of syringes distributed
- # of types of supplies distributed (not count of individual items)
- # of trainings on harm reduction (e.g., overdose prevention, safer use practice, disease prevention) provided to participants
- # of participants trained on harm reduction (e.g., overdose prevention, safer use practice, disease prevention)
- # of participants referred to Treatment Services for OUD
- # of participants referred to Mental Health Services
- # of participants referred to Primary Care Services
- # of participants referred to Employment Resources
- # of participants referred to Housing Resources
- # of naloxone kits distributed
- # of unique participants, who use opioids and/or have OUD, served who report they have enough sterile syringes to cover every injection between SSP visits AND total # of unique participants, who use opioids and/or have OUD, served
- # of participants trained who increased their knowledge of harm reduction practices AND total # of participants trained on harm reduction (e.g., overdose prevention, safer use practice, disease prevention)
- # of participants engaged with SSP services at 6 months AND total # of unique participants, who use opioids and/or have OUD, served
- # of participants who adhere to treatment at 6 months AND total # of unique participants, who use opioids and/or have OUD, served
- # of participants using mental health services at 6 months AND total # of unique participants, who use opioids and/or have OUD, served
- # of participants with OUD using primary healthcare services at 6 months AND total # of unique participants, who use opioids and/or have OUD, served
- # of participants who have obtained employment at 6 months, through engagement with recovery support services AND total # of unique participants, who use opioids and/or have OUD, served
- # of participants who retain housing at 6 months, through engagement with recovery support services AND total # of unique participants, who use opioids and/or have OUD, served
- # of participants who report getting the social and emotional support they need AND total # of unique participants, who use opioids and/or have OUD, served
- # of community overdose reversals using naloxone
- Other (please list): _____

Exhibit A Strategy 10 ‘Criminal justice diversion programs’

***REQUIRED* # of unique participants who have OUD, served**

● Of the # of unique participants who have OUD, served in the count above, how many people identified as:

- **American Indian/Alaska Native Non-Hispanic**
- **Asian Non-Hispanic**
- **Black Non-Hispanic**
- **Native Hawaiian or Other Pacific Islander Non-Hispanic**
- **White Non-Hispanic**
- **Hispanic**
- **Some Other Race or Multiple Races**
- **Unknown**

- # of 911 calls with primary concern related to substance use
- # of dispositions where person was transported to services by law enforcement
- # of dispositions where person was stabilized in community
- # of arrest diversion referrals to pre-arrest diversion programs by law enforcement
- # of social referrals to pre-arrest diversion programs by law enforcement
- # of intakes for pre-arrest diversion programs completed
- # of unique participants enrolled in pre-arrest diversion programs
- # of full-time pre-arrest diversion program staff
- # of participants on staff caseload (average)
- # of contacts with pre-arrest diversion program participants per month
- # of people arrested who are screened for OUD
- # of referrals to post-arrest diversion programs by jail/correctional staff
- # of intakes for post-arrest diversion programs completed
- # of unique participants enrolled in post-arrest diversion programs
- # of dedicated post-arrest diversion program staff
- # of contacts with post-arrest diversion program participants per month
- # of people at intake with no fixed address or address is shelter
- # of referrals to pre-trial service programs by court staff
- # of intakes for pre-trial service programs completed
- # of unique participants enrolled in pre-trial service programs
- # of contacts with pre-trial service program participants per month
- # of initial hearings annually for people identified as having opioid use disorder
- # of participants who use opioids and/or have OUD, referred to addiction treatment
- # of participants who use opioids and/or have OUD, referred to recovery supports (e.g., employment services, housing services, etc.)
- # of participants who use opioids and/or have OUD, referred to harm reduction services (e.g., syringe and supply access, overdose prevention education, disease prevention, etc.)
- # of participants who use opioids and/or have OUD, referred to primary healthcare
- # of participants who use opioids and/or have OUD, referred to other services
- # of participants who use opioids and/or have OUD, provided addiction treatment
- # of participants who use opioids and/or have OUD, provided with recovery support services (e.g., employment services, housing services, etc.)
- # of participants who use opioids and/or have OUD, provided with harm reduction services
- # of participants who use opioids and/or have OUD, provided with primary healthcare services
- # of participants who use opioids and/or have OUD, provided with other services
- # of naloxone kits provided
- # of unique participants, who use opioids and/or have OUD, served, who report they are satisfied with services **AND**

total # of unique participants, who use opioids and/or have OUD, served

- # of 911 calls with primary concern related to substance use AND total # of 911 calls
- # of people arrested who screen positive for OUD AND total # of people arrested who are screened for OUD
- # of law enforcement officers who have referred to diversion program AND total # of law enforcement officers
- # of unique participants, who use opioids and/or have OUD, served, who are connected to services AND total # of unique participants, who use opioids and/or have OUD, served
- # of unique participants, who use opioids and/or have OUD, served, who have been provided with services AND total # of unique participants, who use opioids and/or have OUD, served
- # of referrals that resulted in enrollment in diversion program AND total # of referrals to diversion programs
- # of participants who use opioids and/or have OUD, referred to addiction treatment, who adhere to treatment at 6 months AND total # of participants who use opioids and/or have OUD, referred to addiction treatment
- # of participants who # of participants who have obtained employment at 6 months AND total # of participants who use opioids and/or have OUD, referred to recovery supports (e.g., employment services, housing services, etc.)
- # of participants who retain housing at 6 months AND total # of participants who use opioids and/or have OUD, referred to recovery supports (e.g., employment services, housing services, etc.)
- # of unique participants with OUD served who were referred to harm reduction services and remained engaged with harm reduction services AND total # of participants who use opioids and/or have OUD, referred to harm reduction services (e.g., syringe and supply access, overdose prevention education, disease prevention, etc.)
- # of participants with OUD using primary healthcare services at 6 months AND total # of participants who use opioids and/or have OUD, referred to primary healthcare
- # of participants with OUD using other services at 6 months AND total # of participants who use opioids and/or have OUD, referred to other services
- Other (please list): _____

Exhibit A Strategy 11 ‘Addiction treatment for incarcerated persons’

***REQUIRED* # of unique participants who have OUD, served**

● Of the # of unique participants who have OUD, served in the count above, how many people identified as:

- American Indian/Alaska Native Non-Hispanic
- Asian Non-Hispanic
- Black Non-Hispanic
- Native Hawaiian or Other Pacific Islander Non-Hispanic
- White Non-Hispanic
- Hispanic
- Some Other Race or Multiple Races
- Unknown

- # of people who are incarcerated screened as having OUD
- # of people who are incarcerated who receive methadone for OUD
- # of people who are incarcerated who receive buprenorphine for OUD
- # of people who are incarcerated who receive naltrexone for OUD
- # of group classes, for people who are incarcerated, held on overdose prevention
- # of people who are incarcerated that attended group classes on overdose prevention
- # of group classes, for staff, held on overdose prevention
- # of staff that attended group classes on overdose prevention
- # of naloxone kits distributed to people who were incarcerated upon release
- # of opioid overdose reversals using naloxone within the jail or prison
- # of deaths due to overdose within the jail or prison
- # of referrals made for continued MAT support upon release
- # of people who are incarcerated who receive medication for OUD, who report they are satisfied with services AND total # of people who are incarcerated who receive medication for OUD
- # of people who are incarcerated that are screened for OUD AND total # of people incarcerated
- # of people who increase knowledge about overdose prevention after attending group classes AND total # of people who attended group classes on overdose prevention
- # of referrals made for continued MAT support upon release, that resulted in first appointment AND total # of referrals made for continued MAT support upon release
- # of people released from jail, who receive a naloxone kit upon release AND total # of people released from jail
- # of people who are incarcerated and screen positive as having OUD and then receive methadone in jail AND total # of people who are incarcerated and screen positive as having OUD
- # of people who are incarcerated and screen positive as having OUD and then receive buprenorphine in jail AND total # of people who are incarcerated and screen positive as having OUD
- # of people who are incarcerated and screen positive as having OUD and then naltrexone in jail AND total # of people who are incarcerated and screen positive as having OUD
- # of people who are incarcerated and screen positive as having OUD who started MAT in jail AND total # of people who are incarcerated and screen positive as having OUD
- # of participants who are incarcerated and were on MAT before entering jail, who continued MAT in jail AND total # of participants who are incarcerated and were on MAT before entering jail
- # of deaths due to overdose within the jail AND total # of deaths within the jail
- # of people who are incarcerated screened as having OUD, who report getting the social and emotional support they need AND total # of people who are incarcerated screened as having OUD
- # of community overdose reversals using naloxone
- Other (please list): _____

Exhibit A Strategy 12 'Reentry programs'

***REQUIRED* # of unique participants who use opioids and/or have OUD, enrolled**

• Of the # of unique participants who use opioids and/or have OUD, enrolled in the count above, how many people identified as:

- American Indian/Alaska Native Non-Hispanic**
 - Asian Non-Hispanic**
 - Black Non-Hispanic**
 - Native Hawaiian or Other Pacific Islander Non-Hispanic**
 - White Non-Hispanic**
 - Hispanic**
 - Some Other Race or Multiple Races**
 - Unknown**
- # of written transition case plans developed prior to release
 - # of written transition case plans updated during participation
 - # of case management meetings attended by participants
 - # of OUD treatment sessions attended by participants
 - # of reentry navigators/peer support specialists on staff
 - # of participants provided with harm reduction education
 - # of participants who use opioids and/or have OUD, referred to addiction treatment
 - # of participants who use opioids and/or have OUD, referred to recovery supports (e.g., employment services, housing services, etc.)
 - # of participants who use opioids and/or have OUD, referred to harm reduction services (e.g., syringe and supply access, overdose prevention education, disease prevention, etc.)
 - # of participants who use opioids and/or have OUD, referred to primary healthcare
 - # of participants who use opioids and/or have OUD, referred to other services
 - # of participants who use opioids and/or have OUD, provided addiction treatment
 - # of participants who use opioids and/or have OUD, provided with recovery support services (e.g., employment services, housing services, etc.)
 - # of participants who use opioids and/or have OUD, provided with harm reduction services
 - # of participants who use opioids and/or have OUD, provided with primary healthcare services
 - # of participants who use opioids and/or have OUD, provided with other services
 - # of naloxone kits distributed
 - # of unique participants who use opioids and/or have OUD, enrolled, who report they are satisfied with services AND total # of unique participants who use opioids and/or have OUD, enrolled
 - # of unique participants who use opioids and/or have OUD, enrolled who have an updated transition case plan AND total # of unique participants who use opioids and/or have OUD, enrolled
 - # of case management meetings attended by participants AND total # of case management meetings offered
 - # of OUD treatment sessions attended by participants AND total # of OUD treatment sessions offered
 - # of naloxone kits distributed to participants AND total # of unique participants who use opioids and/or have OUD, enrolled
 - # of unique participants who use opioids and/or have OUD, enrolled, who experience an arrest (i.e., arrest for misdemeanor and/or low-level felony) within 6 months of completing program AND total # of unique participants who use opioids and/or have OUD, enrolled
 - # of participants who use opioids and/or have OUD, referred to addiction treatment who adhered to treatment AND total # of participants who use opioids and/or have OUD, referred to addiction treatment
 - # of participants who use opioids and/or have OUD, who were referred to employment services and obtained employment AND total # of participants who use opioids and/or have OUD, referred to recovery supports (e.g., employment services, housing services, etc.)
 - # of participants who use opioids and/or have OUD, who were referred to housing services and retained housing

AND total # of participants who use opioids and/or have OUD, referred to recovery supports (e.g., employment services, housing services, etc.)

of participants who use opioids and/or have OUD, referred to harm reduction services who remained engaged with harm reduction services AND total # of participants who use opioids and/or have OUD, referred to harm reduction services (e.g., syringe and supply access, overdose prevention education, disease prevention, etc.)

of unique participants with OUD served who were referred to primary healthcare services and who kept using services AND total # of participants who use opioids and/or have OUD, referred to primary healthcare

of unique participants who use opioids and/or have OUD enrolled, who report they are satisfied with services

AND total # of unique participants who use opioids and/or have OUD, enrolled

of community overdose reversals using naloxone

Other (please list): _____